Article
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Melanoma research - 1 Feb 2018
Seremet Teofila, Planken Simon, Schreuer Max, Jansen Yanina, Delaunoy Mélanie, El Housni Hakim, Lienard Danielle, Del Marmol Véronique, Heimann Pierre, Neyns Bart
Abstract excerpt
Anti-programmed death 1 (PD-1) monoclonal antibodies improve the survival of metastatic melanoma patients. Predictive or monitoring biomarkers for response to this therapy could improve the clinical management of these patients. To date, no established biomarkers are available for monitoring the response to immunotherapy. Tumor- specific mutations in circulating tumor DNA (ctDNA) such as BRAF and NRAS mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.